{"id":7031,"date":"2024-10-16T14:34:45","date_gmt":"2024-10-16T06:34:45","guid":{"rendered":"https:\/\/flcube.com\/?p=7031"},"modified":"2024-12-03T20:40:04","modified_gmt":"2024-12-03T12:40:04","slug":"jiangsu-hengruis-hetrombopag-olamine-receives-nmpa-review-for-severe-aplastic-anemia-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=7031","title":{"rendered":"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication"},"content":{"rendered":"\n

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276<\/a>), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has accepted for review another indication approval filing for its drug candidate, hetrombopag olamine. This new indication is for the use of hetrombopag olamine in combination with immunosuppressive therapy to treat patients aged 15 and above with newly diagnosed severe aplastic anemia (SAA).<\/p>\n\n\n\n

Herombopag olamine, a highly selective non-peptide drug similar to Novartis\u2019 Revolade (eltrombopag olamine), received approval in China in June 2021 for the treatment of chronic primary immune thrombocytopenia (ITP) that has not responded well to treatments such as glucocorticoids and immunoglobulins due to thrombocytopenia and clinical conditions that increase the risk of bleeding. The drug also obtained conditional market approval for the treatment of adult patients with severe aplastic anemia (SAA) who do not respond to immunosuppressive therapy.<\/p>\n\n\n\n

The current filing is supported by the positive results of the Phase III HR-TPO-SAA-\u2162 study, which enrolled a total of 240 patients aged 15 and above with newly diagnosed SAA and reached its pre-set primary endpoint in May 2024. The study demonstrated that herombopag olamine was significantly superior to the control group in the primary endpoint, exhibiting good safety and efficacy in long-term treatment. No new safety signals were identified compared to other TPO receptor agonists.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has…<\/p>\n","protected":false},"author":1,"featured_media":7032,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2586,38,852],"class_list":["post-7031","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hengrui-pharmaceuticals","tag-market-approval-filings","tag-sha-600276"],"yoast_head":"\nJiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has accepted for review another indication approval filing for its drug candidate, hetrombopag olamine. This new indication is for the use of hetrombopag olamine in combination with immunosuppressive therapy to treat patients aged 15 and above with newly diagnosed severe aplastic anemia (SAA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=7031\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=7031\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-16T06:34:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T12:40:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"689\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7031#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7031\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication\",\"datePublished\":\"2024-10-16T06:34:45+00:00\",\"dateModified\":\"2024-12-03T12:40:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7031\"},\"wordCount\":231,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7031#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg\",\"keywords\":[\"Hengrui Pharmaceuticals\",\"Market approval filings\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7031#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7031\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=7031\",\"name\":\"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7031#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7031#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg\",\"datePublished\":\"2024-10-16T06:34:45+00:00\",\"dateModified\":\"2024-12-03T12:40:04+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has accepted for review another indication approval filing for its drug candidate, hetrombopag olamine. This new indication is for the use of hetrombopag olamine in combination with immunosuppressive therapy to treat patients aged 15 and above with newly diagnosed severe aplastic anemia (SAA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7031#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7031\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7031#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg\",\"width\":1080,\"height\":689,\"caption\":\"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7031#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication - Insight, China's Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has accepted for review another indication approval filing for its drug candidate, hetrombopag olamine. This new indication is for the use of hetrombopag olamine in combination with immunosuppressive therapy to treat patients aged 15 and above with newly diagnosed severe aplastic anemia (SAA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=7031","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=7031","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-10-16T06:34:45+00:00","article_modified_time":"2024-12-03T12:40:04+00:00","og_image":[{"width":1080,"height":689,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=7031#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=7031"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication","datePublished":"2024-10-16T06:34:45+00:00","dateModified":"2024-12-03T12:40:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=7031"},"wordCount":231,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=7031#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg","keywords":["Hengrui Pharmaceuticals","Market approval filings","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=7031#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=7031","url":"https:\/\/flcube.com\/?p=7031","name":"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=7031#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=7031#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg","datePublished":"2024-10-16T06:34:45+00:00","dateModified":"2024-12-03T12:40:04+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has accepted for review another indication approval filing for its drug candidate, hetrombopag olamine. This new indication is for the use of hetrombopag olamine in combination with immunosuppressive therapy to treat patients aged 15 and above with newly diagnosed severe aplastic anemia (SAA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=7031#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=7031"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=7031#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg","width":1080,"height":689,"caption":"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=7031#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Hengrui\u2019s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/a6fba8c6-b8ab-4378-982b-ecc79b4729cf.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7031"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7031\/revisions"}],"predecessor-version":[{"id":16473,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7031\/revisions\/16473"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/7032"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}